Skip to Main Content
Professional Photo

Jeffrey I. Davis

Of Counsel/Senior Advisor

Jeff Davis advises health care providers and other clients on legal and policy matters, including assistance with the complex issues surrounding the 340B drug pricing program as well as Medicare and Medicaid billing and reimbursement issues.

Featured Videos

How Health Care Organizations Can Take Advantage of Increased Federal Funding of COVID-19-Related Costs March 11, 2021
2021 Health Care Outlook February 16, 2021
Key Insights to Prepare for CARES Act Provider Relief Fund Compliance and Enforcement December 15, 2020

Professional Biography

Mr. Davis provides clients with health care regulatory counsel on issues affecting health care providers, including Medicare and Medicaid billing and reimbursement. He assists hospitals, pharmacies, other health care providers, and vendors on issues related to the federal 340B drug pricing program, including enrollment; contracting; audits; compliance with 340B, Medicare, and Medicaid requirements; and self-disclosures. He also provides clients with strategic advice related to public policy issues before the U.S. Congress and the administration, including drug pricing and non-profit hospital issues.

Prior to joining the Firm, Mr. Davis served as vice president and legislative and policy counsel for 340B Health, a nonprofit organization of more than 1,300 hospitals and health systems participating in the 340B drug pricing program. During his more than seven years with 340B Health, he provided hospitals with technical assistance on 340B, Medicare, and Medicaid program compliance issues, oversaw research and policy efforts, and helped lead the government relations team in their work to educate members of Congress and their staff on the importance of the 340B program to hospitals and their patients. Mr. Davis is also a frequent speaker at major industry forums, making regular presentations at annual 340B Coalition conferences, state hospital association meetings, drug manufacturer conferences, and other professional association events.

Mr. Davis previously served as the health care legislative assistant for U.S. Representative Shelley Berkley (D-NV), where he advised Rep. Berkley on health care issues and legislation before Congress and the House Ways and Means Committee and partnered with health care providers to promote increased Medicare funding for hospitals, physicians, nursing homes, acute care and long term care facilities, and other providers.

Mr. Davis is the co-chair of Baker Donelson's Health Care Reimbursement Group and is the co-editor of Payment Matters, Baker Donelson's publication on Medicare and Medicaid payment issues and other reimbursement issues affecting health care providers. 

  • Named a Best Lawyers in America® "Ones to Watch" in Administrative/Regulatory Law  (2022)
  • "340B Program Latest Developments: 340B-Related Litigation, HHS Advisory Opinion, New Dispute Process Final Rule," Strafford Webinar (June 2020)
  • "Demystifying 340B for Correctional Institutions," National Hepatitis Corrections Network (NHCN) and the National Viral Hepatitis Roundtable webinar (NVHR) (March 2021)
  • "Contract Pharmacy Basics," 340B Coalition Winter Conference (February 2021)
  • "340B Contract Pharmacy Arrangements: What Does the Future Hold?," Strafford webinar (January 2021)
  • "CARES Act for Hospitals and Healthcare Providers: Implications of Key Provisions," Strafford webinar (May 2020)
  • "340B Demystified," National Viral Hepatitis Roundtable webinar (January 2020)
  • "Legislative and Regulatory Update," Alabama Hospital Association (AlaHA) Education Series 340B Day, Montgomery, Alabama (January 2020)
  • "Developments in Drug Pricing – The Changing Landscape for PBMs, Hospitals and Physicians," Practicing Law Institute's "Hot Topics in Health Care Law 2019," New York, New York (December 2019)
  • "Value-Based Reimbursement and Alternative Payment Models," Association of American Cancer Institute's (AACI)/Cancer Center Administrators Forum (CCAF) Annual Meeting, Washington, D.C. (October 2019)
  • "340B Basics and Oversight Updates," American Health Law Association (AHLA) Annual Meeting (June 2019)
  • "AHLA 2019 Annual Meeting in Boston" (June 2019)
  • "340B Legislative Update," 340B Coalition Winter Conference (January 2019)
  • "Exploring Changes to Medicare Part B Drug Reimbursement," 340B Coalition Winter Conference (January 2019)
  • "Community Benefit Reporting and Community Health Needs Assessment," 340B Coalition Winter Conference (January 2019)
  • "International Pricing Index Payment Model," 340B Health Webinar (November 2018)
  • "340B Drug Pricing Program: Past, Present and Future," D.C. Bar panel (September 2018)
  • "The Impact of 340B Reimbursement Cuts on Cancer Centers," Association of American Cancer Institutes (AACI) webinar (September 2018)
  • "Update and Submitting Comments on 2019 Proposed OPPS Rule," 340B Health Webinar (August 2018)
  • "340B Legislative Update," 340B Coalition Annual Conference (July 2018)
  • "Medicare Payment Cuts to 340B Hospitals — Financial and Operational Impact," 340B Coalition Annual Conference (July 2018)
  • "Understanding Medicare Provider Based Rules and Implications for 340B Child Site Registration," 340B Coalition Annual Conference (July 2018)
  • "PBM Panel Discussion," American Pharmacy Purchasing Alliance Pharmacon Expo (June 2018)
  • "340B Legislative Update," 340B Coalition Winter Conference (February 2018)
  • "Medicare Payment Cuts to 340B Hospitals: Operationalizing Modifiers and Evaluating Next Steps," 340B Coalition Winter Conference (February 2018)
  • "Navigate the Complexities of 340B and Its Impact on Pricing and Contracting," Reimbursement and Contracting (September 2017)
  • "340B Self-Disclosures," Medicaid Drug Rebate Program Summit (September 2017)
  • "Covered Entity Operational Insights and Case Study Examples," 340B Manufacturer Summit (August 2017)
  • "340B and Specialty Drugs," 340B Coalition Annual Conference (July 2017)
  • "Managing the Implementation and Operational Challenges Resulting from Significant Changes to the 340B Program," 11th "Big Four" Pharmaceutical Pricing Boot Camp (May 2017)
  • "Medicaid Billing and Reimbursement," 340B Coalition Winter Conference (February 2017)
  • "Orphan Drugs, Left Without a Home: The Impact of 340B Exclusions," Iowa Hospital Association Annual Meeting (October 2016)
  • "340B Essentials," Florida Institute of Certified Public Accountants Health Care Industry Conference (April 2016)


  • Boston University School of Law, J.D., 2010
    • Boston University Public Interest Law Journal, managing editor
  • University of Maryland, B.A., 2005, magna cum laude


  • District of Columbia, 2018
  • Maryland, 2010

Email Disclaimer

NOTICE: The mailing of this email is not intended to create, and receipt of it does not constitute an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.
Cancel Accept